The New DTC Guidelines
In January, for the first time since 1998, the FDA announced changes to the regulations that govern the content and format of the product disclaimer or brief summary that must accompany print advertising of DTC products. The FDA revealed three new draft guidelines for the $2.6 billion DTC industry, which would have pharma companies revamp and reduce the brief summaries in print ads and encourage more disease awareness spots on TV.
PharmaVOICE asked what your suggestions would be to the FDA on how these guidances can advance public health and at the same time observe smart business tactics.
Less is Not More
Robin Shapiro, President, Health Advocacy Strategies, LLC
Less is Still Not More
Rob McMichael, Associate Creative Director, Copy, Strategic Medical Communications, a division of Healthstar Advertising Inc.
E-mail and Web are More Cost-effective
Andy Weissberg, Executive VP, CPRi Communications
FDA Efforts Can Help Legitimize DTC
Andy Galler, Chief Scientific Officer, AlphaMedica Inc.
FDA Needs to be Realistic
Mark S. Perlotto, Executive VP, General Manager, Adair-Greene Healthcare Communications
More Portable Technology
My Cellphone is My Lifeline
Jeff Lipman, Executive VP, Creative Director, Integrity Healthcare Communications
WiFi Aids Communication
Ken Begasse Jr., Partner and Director of Client Services, Concentric Healthcare Advertising